Department of Internal Medicine, Myongji Hospital, Hanyang University, Gyeonggi-do, Republic of Korea.
These authors contributed equally to this work.
Eur Respir J. 2023 Jul 7;62(1). doi: 10.1183/13993003.00291-2023. Print 2023 Jul.
We aimed to study whether statin use is associated with lowering the development of interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF).
The study population was the Korean National Health Insurance Service-Health Screening Cohort. ILD and IPF cases were identified using diagnosis codes (J84.1 for ILD and J84.1A as a special code for IPF) based on the International Classification of Diseases, 10th Revision. The study participants were followed up from 1 January 2004 to 31 December 2015. Statin use was defined by the cumulative defined daily dose (cDDD) per 2-year interval and participants were categorised into never-users, <182.5, 182.5-365.0, 365.0-547.5 and ≥547.5 by cDDD. A Cox regression was used to fit models with time-dependent variables of statin use.
Incidence rates for ILD with and without statin use were 20.0 and 44.8 per 100 000 person-years, respectively, and those for IPF were 15.6 and 19.3 per 100 000 person-years, respectively. The use of statins was independently associated with a lower incidence of ILD and IPF in a dose-response manner (p-values for trend <0.001). ILD showed respective adjusted hazard ratios (aHRs) of 1.02 (95% CI 0.87-1.20), 0.60 (95% CI 0.47-0.77), 0.27 (95% CI 0.16-0.45) and 0.24 (95% CI 0.13-0.42) according to the increasing category of statin use compared with never-users. IPF showed respective aHRs of 1.29 (95% CI 1.07-1.57), 0.74 (95% CI 0.57-0.96), 0.40 (95% CI 0.25-0.64) and 0.21 (95% CI 0.11-0.41).
A population-based cohort analysis found that statin use is independently associated with a decreased risk of ILD and IPF in a dose-response manner.
本研究旨在探讨他汀类药物的使用是否与降低间质性肺病（ILD）和特发性肺纤维化（IPF）的发展有关。
研究人群为韩国国家健康保险服务-健康筛查队列。ILD 和 IPF 病例是根据国际疾病分类，第 10 版（ICD-10）的诊断代码（J84.1 用于ILD 和 J84.1A 是 IPF 的特殊代码）确定的。研究参与者从 2004 年 1 月 1 日至 2015 年 12 月 31 日进行随访。他汀类药物的使用通过每 2 年间隔的累积定义日剂量（cDDD）来定义，参与者根据 cDDD 分为从未使用者、<182.5、182.5-365.0、365.0-547.5 和≥547.5。使用 Cox 回归拟合具有他汀类药物使用时间依赖性变量的模型。
ILD 和 IPF 的发生率分别为每 100000 人年 20.0 和 44.8 例，以及每 100000 人年 15.6 和 19.3 例。他汀类药物的使用与 ILD 和 IPF 的发生呈剂量反应关系，呈独立相关（趋势检验 p 值均<0.001）。ILD 分别调整后的危险比（aHR）为 1.02（95% CI 0.87-1.20）、0.60（95% CI 0.47-0.77）、0.27（95% CI 0.16-0.45）和 0.24（95% CI 0.13-0.42），与从未使用者相比，他汀类药物使用量呈递增趋势。IPF 分别为 1.29（95% CI 1.07-1.57）、0.74（95% CI 0.57-0.96）、0.40（95% CI 0.25-0.64）和 0.21（95% CI 0.11-0.41）。
基于人群的队列分析发现，他汀类药物的使用与 ILD 和 IPF 的风险降低呈剂量反应关系。
